The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
May 1st 2024
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
Dr. Aft on Disseminating Tumor Cells and Prognosis
June 14th 2013Rebecca L. Aft, MD, PhD, discusses the identification of patients with breast cancer at high risk of recurrent disease development by detection of HER2-positive disseminated tumor cells in bone marrow of patients with HER2-negative tumors.
Leading Oncologists Analyze Impact of New HER2 Research on Clinical Practice
June 11th 2013Although recent findings suggest some patients with HER2-negative breast cancer would benefit from therapies directed against overexpression of the protein, two leading oncologists do not see an immediate impact on clinical practice as further validation is needed.
HER2 Mutations Identified as Treatment Targets in Patients With HER2-Negative Breast Cancer
Patients with breast cancer who do not exhibit amplifications of the HER2 gene may still have mutations of HER2 that drive the progression of their cancer, suggesting that these mutations could serve as therapeutic targets.
Addition of PI3K Inhibitor May Prevent or Delay Resistance to Therapy in HER2+ Breast Cancer
A new study found that patients with HER2-positive breast cancer who are receiving anti-HER2 therapy could prevent or delay resistance when a phosphatidylinositol-3 kinase (PI3K) inhibitor is added during treatment.
Lapatinib Plus Trastuzumab Bests Lapatinib Monotherapy in HER2-Positive Metastatic Breast Cancer
Investigators have documented a significant 4.5-month median overall survival advantage with lapatinib combined with trastuzumab in women with heavily pretreated HER2-positive metastatic breast cancer.